SITE010-0205

SITE010 (ESP) › SITE010-0205

SITE010-0205

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2026-05-04

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 2 Pruritus — outcome: RECOVERED/RESOLVED; onset 2023-02-02 (study day 88); relationship: not assessed

moderate assessed

Grade 3 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-11-28 (study day 22); relationship: NOT RELATED

severe assessed

Data queries

0

No data queries. Open queries would appear here for this patient.